| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/BBRC.1997.6853 |
| P698 | PubMed publication ID | 9207232 |
| P2093 | author name string | Fielding K | |
| Johnston P | |||
| Ranganathan S | |||
| Rosen E | |||
| Laterra J | |||
| Nam M | |||
| P433 | issue | 3 | |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 743-747 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth | |
| P478 | volume | 235 |
| Q37480801 | Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity |
| Q30428363 | An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth |
| Q94367553 | Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation |
| Q24606703 | Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation |
| Q34203095 | DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. |
| Q30851343 | Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5 |
| Q44785670 | Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. |
| Q44421351 | Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. |
| Q38712457 | Immune microenvironment of gliomas |
| Q37939411 | Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. |
| Q37312752 | Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q34283477 | Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas. |
| Q39819576 | Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway |
| Q55457289 | Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. |
| Q48173251 | Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. |
| Q40894843 | Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene |
| Q33778706 | Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas |
| Q48182286 | Scatter factor/hepatocyte growth factor gene transfer increases rat blood-glioma barrier permeability |
| Q24683896 | Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis |
| Q34277050 | Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription |
| Q32134611 | Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. |
| Q48635543 | The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival |
| Q38008966 | The molecular profile of microglia under the influence of glioma |
| Q52316580 | The multiple paths towards MET receptor addiction in cancer. |
| Q36289377 | The role of semaphorins and their receptors in gliomas |
| Q48462548 | Tumor growth instability and the onset of invasion |
| Q36249219 | Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro |
| Q30428632 | XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. |
| Q35049178 | c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. |
| Q47588979 | c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells |
Search more.